TET Systems Signs License Agreement with Stemgent
News Feb 13, 2009
TET Systems Holding, Stemgent, Inc., and Clontech Laboratories, Inc., announced that they have entered into a partnership enabling Stemgent to market certain research reagents for inducible stem cell technology based on the Tet Technology.
Stemgent will be applying TET Systems' Tet Technology, based on essential regulatory components of the E. coli tetracycline-resistance operon, to its suite of viral vector systems for the generation of induced pluripotent stem (iPS) cells. Once established in the cell line, the inducer doxycycline, a tetracycline derivative, controls the system in a dose-dependent manner, allowing researchers to precisely modulate the expression levels of target genes such as Oct4, Sox2, and other transcription factors identified as important in generation of iPS cells.
The journal Science proclaimed reprogramming - the process by which cells are manipulated from a differentiated state to a pluripotent state, down a new pathway, or directly from one differentiated state to another - to be the Breakthrough of the Year in December 2008.
By licensing this technology from TET Systems, Stemgent is now able to provide more sophisticated tools to the research communities it serves, furthering its mission of advancing stem cell science.
"We are excited to enter into partnership with TET Systems," added Dr. Stephen Chang, Chief Scientific Officer of Stemgent. "Dr. Hermann Bujard's pioneering work with the Tet Technology has enabled tremendous advances in developmental biology and, now, stem cell sciences."
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019